High-sensitive fluorescent energy transfer assay using fluorescent amino acids and fluoresent proteins
US-2015369800-A1 · Dec 24, 2015 · US
US9664677B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9664677-B2 |
| Application number | US-201113090199-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 19, 2011 |
| Priority date | Apr 19, 2010 |
| Publication date | May 30, 2017 |
| Grant date | May 30, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A composition can include a complex, where the complex includes a photoluminescent nanostructure and a polymer free from selective binding to an analyte, the polymer adsorbed on the photoluminescent nanostructure, and a selective binding site associated with the complex.
Opening claim text (preview).
What is claimed is: 1. A composition, comprising: a complex, wherein the complex includes: a nanostructure, wherein the nanostructure is a photoluminescent nanostructure, wherein the photoluminescent nanostructure is a single-walled carbon nanotube; and a polymer, the polymer adsorbed on the nanostructure and the polymer being free from selective binding to an analyte in the absence of being adsorbed on the nanostructure, wherein the polymer is a boronic acid functionalized phenoxy dextran; and a selective binding site for the analyte on the complex. 2. The composition of claim 1 , wherein the analyte is a monosaccharide, a polysaccharide, an amino acid, a nucleotide, an oligonucleotide, a lipid, a polylipid, a steroid, a peptide, a protein, riboflavin, or nitric oxide. 3. The composition of claim 1 , wherein the analyte is 17-α-estradiol, 2,4-dinitrophenol, acetylcholine chloride, α-tocopherol, adenosine, adenosine-5′-triphosphate, cyclic adenosine monophosphate, creatinine, cytidine, D-aspartic acid, D-fructose, D-galactose, D-glucose, D-mannose, dopamine, glycine, guanosine, histamine, L-ascorbic acid, L-citrulline, L-histidine, L-thyroxine, melatonin, NADH, quinine, salicylic acid, serotonin, sodium azide, sodium pyruvate, sucrose, thymidine, tryptophan, tyramin or urea. 4. The composition of claim 1 , further comprising an amount of the analyte. 5. The composition of claim 4 , wherein the analyte is a therapeutic. 6. A system comprising: the composition of claim 1 ; an electromagnetic radiation source having an excitation wavelength directed at the composition; and a detector configured to receive an emission wavelength from the composition.
with steric inhibition or signal modification, e.g. fluorescent quenching · CPC title
Nanotechnology for materials or surface science, e.g. nanocomposites · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.